EUVIMEDEUVIMED entdecken
Crossref

Immo-bile-izing CD8+ T cell anti-tumor immunity

Scott A Read, Golo Ahlenstiel

Immunity · 2025

DOI: 10.1016/j.immuni.2025.02.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunity, 2025. Verfasst von Scott A Read und 1 weiteren Autor:innen. Beteiligte Einrichtung: Blacktown Clinical School, Western Sydney University, Sydney, NSW 2148, Australia; Storr Liver Centre, Westmead Institute for Medical Research, Sydne…. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Liver Neoplasms, Carcinoma, Hepatocellular, Bile Acids and Salts. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma is poorly responsive to immune checkpoint blockade. In a recent issue of Science, Varanasi et al. reveal how bile acids dampen anti-tumor CD8+ T cell responses in the liver, contributing to cancer progression and poor immunotherapy outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesLiver NeoplasmsCarcinoma, HepatocellularBile Acids and SaltsNeoplasmsHumansAnimalsImmunotherapyImmune Checkpoint Inhibitors

Substanzen

Bile Acids and SaltsImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Blacktown Clinical School, Western Sydney University, Sydney, NSW 2148, Australia; Storr Liver Centre, Westmead Institute for Medical Research, Sydney, NSW 2145, Australia; Blacktown Mt Druitt Hospital, Sydney, NSW 2148…

Zitieren

APA

Read, S. A., & Ahlenstiel, G. (2025). Immo-bile-izing CD8+ T cell anti-tumor immunity. Immunity. https://doi.org/10.1016/j.immuni.2025.02.015

Vancouver

Read SA, Ahlenstiel G. Immo-bile-izing CD8+ T cell anti-tumor immunity. Immunity. 2025. doi:10.1016/j.immuni.2025.02.015

BibTeX
@article{Read2025,
  author = {Read, Scott A and Ahlenstiel, Golo},
  title = {Immo-bile-izing CD8+ T cell anti-tumor immunity},
  journal = {Immunity},
  year = {2025},
  doi = {10.1016/j.immuni.2025.02.015}
}
Kostenlos starten →